These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31761273)

  • 21. How Single-payer Stacks Up: Evaluating Different Models of Universal Health Coverage on Cost, Access, and Quality.
    Fox A; Poirier R
    Int J Health Serv; 2018 Jul; 48(3):568-585. PubMed ID: 29925286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Canadian Health Care System: Who Should Pay for All Medically Beneficial Treatments? A Burning Issue.
    Chowdhury MZI; Chowdhury MA
    Int J Health Serv; 2018 Apr; 48(2):289-301. PubMed ID: 29095077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Six Myths About Pharmacare.
    Lexchin J
    Health Law Can; 2017 Feb; 37(2-3):44-51. PubMed ID: 30005520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Canadian pharmacare: looking back, looking forward.
    Morgan SG; Daw JR
    Healthc Policy; 2012 Aug; 8(1):14-23. PubMed ID: 23968600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Socioeconomic differences in prescription drug supplemental coverage in Canada: A repeated cross-sectional study.
    Guo EX; Sweetman A; Guindon GE
    Health Policy; 2020 Mar; 124(3):252-260. PubMed ID: 31952864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries.
    Kennedy J; Morgan S
    Clin Ther; 2009 Jan; 31(1):213-9. PubMed ID: 19243719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmaceutical policy reform in Canada: lessons from history.
    Boothe K
    Health Econ Policy Law; 2018 Jul; 13(3-4):299-322. PubMed ID: 29388519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries.
    Morgan SG; Lee A
    BMJ Open; 2017 Jan; 7(1):e014287. PubMed ID: 28143838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs?
    Coombes ME; Morgan SG; Barer ML; Pagliccia N
    Healthc Q; 2004; 7(4):suppl 13-9. PubMed ID: 15540402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countries.
    Barnieh L; Manns B; Harris A; Blom M; Donaldson C; Klarenbach S; Husereau D; Lorenzetti D; Clement F
    Value Health; 2014; 17(1):98-108. PubMed ID: 24438723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Other considerations than: how much will universal health coverage cost?
    Barber SL; O'Dougherty S; Vinyals Torres L; Tsilaajav T; Ong P
    Bull World Health Organ; 2020 Feb; 98(2):95-99. PubMed ID: 32015579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distributional consequences of the transition from age-based to income-based prescription drug coverage in British Columbia, Canada.
    Hanley GE; Morgan S; Hurley J; van Doorslaer E
    Health Econ; 2008 Dec; 17(12):1379-92. PubMed ID: 18189226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of prescription drug insurance on cost related non-adherence to medications in Canada: A Heckman sample selection approach.
    Zhang Q; Laporte A
    PLoS One; 2023; 18(8):e0289776. PubMed ID: 37556420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
    Blumberg DM; Prager AJ; Liebmann JM
    JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reforming private drug coverage in Canada: inefficient drug benefit design and the barriers to change in unionized settings.
    O'Brady S; Gagnon MA; Cassels A
    Health Policy; 2015 Feb; 119(2):224-31. PubMed ID: 25498311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The value and consequences of using public health technology assessments for private payer decision-making in Canada: one size does not fit all.
    Pericleous L; Amin M; Goeree R
    J Med Econ; 2019 May; 22(5):478-487. PubMed ID: 30757934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A National Approach to Reimbursement Decision-Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds.
    Short H; Stafinski T; Menon D
    Healthc Policy; 2015 May; 10(4):24-46. PubMed ID: 26142357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Political Economy of Reform under US Federalism: Adopting Single-Payer Health Coverage in New York State.
    Fox AM; Choi Y
    Health Syst Reform; 2019; 5(3):209-223. PubMed ID: 31390296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges To Medicare For All Remain Daunting.
    Frakt AB; Oberlander J
    Health Aff (Millwood); 2020 Jan; 39(1):142-145. PubMed ID: 31905071
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.